Immunovant Reports Financial Results for the Quarter and Six Months Ended September 30, 2020
November 12, 2020 08:00 ET
|
Immunovant
NEW YORK, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases, today...
Immunovant Announces Closing of $200.0 Million Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
September 04, 2020 16:01 ET
|
Immunovant
NEW YORK, Sept. 04, 2020 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases, today...
Immunovant Announces Pricing of Public Offering
September 02, 2020 07:30 ET
|
Immunovant
NEW YORK, Sept. 02, 2020 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT) today announced the pricing of its underwritten public offering of 5,270,093 shares of its common stock at a price to the...
Immunovant Announces Positive Topline Results from Multi-Center, Placebo-Controlled Phase 2a Trial of IMVT-1401, A Novel Investigational Anti-FcRn Antibody Delivered by Subcutaneous Injection, in Myasthenia Gravis
August 25, 2020 07:30 ET
|
Immunovant
3.8-point mean improvement on the Myasthenia Gravis Activities of Daily Living (MG-ADL) scale was statistically significant vs. placebo (p = 0.029)8.0-point mean improvement on Myasthenia Gravis...
Immunovant Appoints Michael Elliott Chief Scientific Officer
August 24, 2020 08:00 ET
|
Immunovant
NEW YORK, Aug. 24, 2020 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases, today...
Immunovant Reports Financial Results for the Quarter Ended June 30, 2020
August 12, 2020 16:01 ET
|
Immunovant
NEW YORK, Aug. 12, 2020 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases, today...
Immunovant Reports Financial Results for the Quarter and Fiscal Year Ended March 31, 2020 and Announces Plans for Phase 3 Registrational Trial of IMVT-1401 in Myasthenia Gravis
June 29, 2020 07:30 ET
|
Immunovant
Based on compelling proof-of-biology for anti-FcRn agents in Myasthenia Gravis (MG), Immunovant has begun preparations to initiate a Phase 3 registrational trial of IMVT-1401 in MGIMVT-1401’s...
Immunovant Announces Redemption of Warrants and Achievement of First Earnout Milestone under Share Exchange Agreement
May 14, 2020 07:30 ET
|
Immunovant
NEW YORK, May 14, 2020 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases, today...
Immunovant Announces Closing of $139.4 Million Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
April 16, 2020 16:01 ET
|
Immunovant
NEW YORK, April 16, 2020 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases, today...
Immunovant Announces Pricing of $121.2 Million Public Offering
April 14, 2020 09:28 ET
|
Immunovant
NEW YORK, April 14, 2020 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases, today...